Compare Cassava Sciences Inc (FLNA) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Simon Property Group Inc — how do they compare? Cassava Sciences Inc trades at $1.1 (market cap $53.14M), while Simon Property Group Inc trades at $222 (market cap $72.00B). The key difference: Simon Property Group Inc is far larger — about 1354.9× Cassava Sciences Inc's market cap, and Simon Property Group Inc pays a 3.96% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | SPG | |
|---|---|---|
Market Cap | $53.14M | $72.00B |
Sector | Health | Real Estate |
52-Week High | $4.64 | $227.56 |
52-Week Low | $1.09 | $160.68 |
Enterprise Value | -$33.43M | $100.48B |
Dividend Yield | — | 3.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
SPG trades at $227.16, up 2.66% today, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, including Q1 2026 EPS of $1.48 versus $1.46 expected. Revenue grew to $6.36B in 2025 with a net income margin of 70.59%, though cash flow trends show a net outflow of -$577M. Analyst consensus is mixed with 40.54% buy ratings but a price target of $214.40 below the current price.
Outlook remains positive due to robust leasing activity and raised guidance, but risks include high leverage with $24.21B long-term debt and sensitivity to interest rates. The stock's valuation metrics like P/E of 15.44 appear reasonable, yet investor caution is warranted given the negative net cash flow and competitive pressures from e-commerce.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
